Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 6/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22958897 | 0.86 | KMT2A (0.47) | CYP2A13ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL28852963 | 0.81 | CYP2A13 (0.75) | CYP2A13CYP2C9ALOX15HSD17B10CXCR4 | |
| SCHEMBL4108854 | 0.80 | CYP2A13 (1.00) | CYP2A13CYP2C9ALOX15HSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11239603 | 0.79 | CYP2A13 (0.96) | CYP2A13CYP2C9ALOX15HSD17B10ALDH1A1 | |
| SCHEMBL28972223 | 0.78 | CYP2A13 (0.71) | CYP2A13CYP2C9ALOX15HSD17B10CXCR4 | |
| SCHEMBL17724132 | 0.78 | CYP2A13 (0.71) | CYP2A13CYP2C9ALOX15HSD17B10CXCR4 | |
| SCHEMBL13849993 | 0.78 | CYP2A13 (0.71) | CYP2A13CYP2C9ALOX15HSD17B10CXCR4 | |
| SCHEMBL9060001 | 0.78 | CYP2A13 (0.71) | CYP2A13CYP2C9ALOX15HSD17B10CXCR4 | |
| SCHEMBL10154384 | 0.76 | CYP2A13 (0.63) | CYP2A13CYP2C9ALOX15HSD17B10CXCR4 | |
| SCHEMBL19532823 | 0.75 | CYP2A13 (0.56) | CYP2A13CYP2C9ALOX15HSD17B10CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2018-07-10 | — | — | US | disclosed |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | IL2, IL1B, IL5 | CYP2A13 1179/4885CYP2C9 313/4885ALOX15 553/4885 |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | IL2, IL1B, IL5 | CYP2A13 1179/4885CYP2C9 313/4885ALOX15 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.